Geoffrey Porges
Stock Analyst at SVB Leerink
(0.28)
# 3,288
Out of 4,667 analysts
132
Total ratings
n/a
Success rate
n/a
Average return
Main Sectors:
Top Industries:
Stocks Rated by Geoffrey Porges
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| PFE Pfizer | Maintains: Market Perform | $52 → $56 | $25.13 | +122.84% | 10 | Dec 15, 2021 | |
| RDUS Radius Recycling | Maintains: Market Perform | $30 → $20 | $19.74 | +1.32% | 10 | Dec 9, 2021 | |
| RCUS Arcus Biosciences | Maintains: Outperform | $68 → $100 | $14.28 | +600.28% | 8 | Nov 18, 2021 | |
| REGN Regeneron Pharmaceuticals | Maintains: Outperform | $798 → $850 | $744.50 | +14.17% | 16 | Nov 5, 2021 | |
| HALO Halozyme Therapeutics | Maintains: Outperform | $50 → $48 | $45.70 | +5.03% | 2 | Nov 3, 2021 | |
| AMGN Amgen | Maintains: Market Perform | $234 → $216 | $289.90 | -25.49% | 12 | Nov 3, 2021 | |
| ABBV AbbVie | Maintains: Outperform | $142 → $135 | $171.73 | -21.39% | 16 | Nov 1, 2021 | |
| ROIV Roivant Sciences | Initiates: Outperform | $11 | $11.82 | -6.94% | 1 | Nov 1, 2021 | |
| GILD Gilead Sciences | Maintains: Outperform | $77 → $75 | $89.76 | -16.44% | 14 | Oct 29, 2021 | |
| SNY Sanofi | Upgrades: Outperform | n/a | $47.98 | - | 2 | Sep 27, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $29 → $10 | $9.61 | +4.06% | 9 | Sep 16, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $35 → $30 | $0.39 | +7,647.93% | 8 | Aug 10, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underperform | $170 → $175 | $450.37 | -61.14% | 9 | Jul 30, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $96 → $84 | $14.72 | +470.65% | 3 | May 10, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $33.70 | - | 1 | Mar 23, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $33 | $3.13 | +954.31% | 1 | Nov 11, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $61 | $14.35 | +325.09% | 2 | Nov 28, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $158.01 | - | 8 | Mar 16, 2017 |
Pfizer
Dec 15, 2021
Maintains: Market Perform
Price Target: $52 → $56
Current: $25.13
Upside: +122.84%
Radius Recycling
Dec 9, 2021
Maintains: Market Perform
Price Target: $30 → $20
Current: $19.74
Upside: +1.32%
Arcus Biosciences
Nov 18, 2021
Maintains: Outperform
Price Target: $68 → $100
Current: $14.28
Upside: +600.28%
Regeneron Pharmaceuticals
Nov 5, 2021
Maintains: Outperform
Price Target: $798 → $850
Current: $744.50
Upside: +14.17%
Halozyme Therapeutics
Nov 3, 2021
Maintains: Outperform
Price Target: $50 → $48
Current: $45.70
Upside: +5.03%
Amgen
Nov 3, 2021
Maintains: Market Perform
Price Target: $234 → $216
Current: $289.90
Upside: -25.49%
AbbVie
Nov 1, 2021
Maintains: Outperform
Price Target: $142 → $135
Current: $171.73
Upside: -21.39%
Roivant Sciences
Nov 1, 2021
Initiates: Outperform
Price Target: $11
Current: $11.82
Upside: -6.94%
Gilead Sciences
Oct 29, 2021
Maintains: Outperform
Price Target: $77 → $75
Current: $89.76
Upside: -16.44%
Sanofi
Sep 27, 2021
Upgrades: Outperform
Price Target: n/a
Current: $47.98
Upside: -
Sep 16, 2021
Maintains: Outperform
Price Target: $29 → $10
Current: $9.61
Upside: +4.06%
Aug 10, 2021
Maintains: Outperform
Price Target: $35 → $30
Current: $0.39
Upside: +7,647.93%
Jul 30, 2021
Maintains: Underperform
Price Target: $170 → $175
Current: $450.37
Upside: -61.14%
May 10, 2021
Maintains: Market Perform
Price Target: $96 → $84
Current: $14.72
Upside: +470.65%
Mar 23, 2021
Downgrades: Market Perform
Price Target: n/a
Current: $33.70
Upside: -
Nov 11, 2020
Initiates: Outperform
Price Target: $33
Current: $3.13
Upside: +954.31%
Nov 28, 2018
Initiates: Outperform
Price Target: $61
Current: $14.35
Upside: +325.09%
Mar 16, 2017
Downgrades: Market Perform
Price Target: n/a
Current: $158.01
Upside: -